Table 3 Univariate analysis: hazards of progression and/or death.

Age

≤65

1

1

>66

1.13 (0.94–1.36)

0.185

1.49 (1.21–1.84)

<0.001

Sex

Male

1

1

Female

0.96 (0.81–1.14)

0.633

0.90 (0.74–1.09)

0.277

Race

White

1

1

Black

0.97 (0.82–1.16)

0.767

0.84 (0.68–1.04)

0.114

Asian

0.84 (0.43–1.63)

0.607

1.15 (0.57–2.32)

0.704

B2M

≤5.5

1

1

>5.5

1.57 (1.22–2.03)

<0.001

1.82 (1.38–2.41)

<0.001

LDH

≤270

1

1

>270

1.93 (1.19–3.13)

0.007

2.76 (1.71–4.46)

<0.001

Calcium

≤10.5

1

1

>10.5

1.53 (1.19–1.98)

<0.001

1.69 (1.28–2.23)

<0.001

Creatinine

≤2

1

1

>2

1.09 (0.81–1.45)

0.582

1.157 (0.84–1.6)

0.378

ISS stage

1

1

1

2

1.21 (0.96–1.53)

0.108

1.27 (0.97–1.67)

0.086

3

1.7 (1.33–2.17)

<0.001

1.97 (1.50–2.59)

<0.001

Cytogenetic risk

Standard-risk

1

1

High-risk

1.81 (1.46–2.25)

<0.001

2.31 (1.82–2.93)

<0.001

RISS stage

1

1

1

2

1.70 (1.29–2.25)

<0.001

1.85 (1.32–2.61)

<0.001

3

3.17 (2.14–4.69)

<0.001

3.8 (2.43–5.95)

<0.001

Induction

DRVd

1

1

RVd

2.99 (1.77–5.03)

<0.001

1.88 (1.04–3.40)

0.037

≤VGPR post-induction

No

1

1

Yes

1.40 (1.17–1.68)

<0.001

1.25 (1.01–1.55)

0.042

≤VGPR post-transplant

No

1

1

Yes

2.10 (1.65–2.68)

<0.001

2.21 (1.70–2.89)

<0.001

Maintenance

Yes

1

1

No

1.51 (1.22–1.85)

<0.001

2.67 (2.17–3.30)

<0.001